Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 19, 2009, Pages 3088-3090

  Febbo, Phillip G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; WNT PROTEIN; TUMOR MARKER;

APC GENE; CANCER GROWTH; DNA METHYLATION; EDITORIAL; EPIGENETICS; GATA2 GENE; GENE; GENE EXPRESSION; GENE SILENCING; GSTP1 GENE; HUMAN; MOLECULAR BIOLOGY; MORTALITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; RUNX3 GENE; SIGNAL TRANSDUCTION; ANIMAL; GENETIC EPIGENESIS; GENETICS; MALE; MOUSE; PROSTATE TUMOR;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; MALE; MICE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650290541     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.9783     Document Type: Editorial

References (16)

1. Richiardi L, Fiano V, Vizzini L, et al: Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 27:3161-3168, 2009
2. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975-1986, 2004
3. Yegnasubramanian S, Haffner MC, Zhang Y, et al: DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68:8954-8967, 2008
4. McLendon R, Friedman A, Bigner D, et al: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
5. Ellinger J, Haan K, Heukamp LC, et al: CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68:42-49, 2008
6. Bastian PJ, Palapattu GS, Lin X, et al: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11:4037-4043, 2005
7. Gonzalgo ML, Pavlovich CP, Lee SM, et al: Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 9:2673-2677, 2003
8. Rosenbaum E, Hoque MO, Cohen Y, et al: Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11:8321-8325, 2005
9. Bastian PJ, Ellinger J, Heukamp LC, et al: Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 51:665-674, 2007; discussion 674
10. Woodson K, O'Reilly KJ, Ward DE, et al: CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 1:183-186, 2006
11. Henderson CJ, Smith AG, Ure J, et al: Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci U S A 95:5275-5280, 1998
12. Gate L, Majumdar RS, Lunk A, et al: Influence of glutathione S-transferase pi and p53 expression on tumor frequency and spectrum in mice. Int J Cancer 113:29-35, 2005
13. Bruxvoort KJ, Charbonneau HM, Giambernardi TA, et al: Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67:2490-2496, 2007
14. Rosenbaum E, Carducci MA: Pharmacotherapy of hormone refractory prostate cancer: New developments and challenges. Expert Opin Pharmacother 4:875-887, 2003
15. Ellinger J, Bastian PJ, Jurgan T, et al: CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71:161-167, 2008
16. Ung JO, Richie JP, Chen MH, et al: Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60:458-463, 2002